Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBADr. Arsela Prelaj
Lead Investigator and Medical Oncologist, I3LUNG
- Industry
- Precision oncology and multimodal AI
- Based in
- Milan, Italy
- Company funding
- Undisclosed
- Region
- Europe
Medical oncologist at IRCCS Istituto Nazionale dei Tumori in Milan.
Leads the I3LUNG consortium, whose explainable AI for metastatic lung cancer was validated in Nature Medicine across 2,396 patients.
[]
Related on The Signal
Dr. Dereck Mush, MD, MBA
Inside TumorSight Risk: What MRI-Based Recurrence Assessment Can and Cannot Tell Clinicians
Dr. Dereck Mush, MD, MBA
Inside SimBioSys TumorSight Risk: Bringing Recurrence Assessment Into the MRI Workflow
Dr. Dereck Mush, MD, MBA
Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBAKeep exploring